Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Int Arch Allergy Immunol. 2012;157(3):215-25. doi: 10.1159/000328760. Epub 2011 Oct 27.
Activation of tissue mast cells (MCs) and their abnormal growth and accumulation in various organs are typically found in primary MC disorders also referred to as mastocytosis. However, increasing numbers of patients are now being informed that their clinical findings are due to MC activation (MCA) that is neither associated with mastocytosis nor with a defined allergic or inflammatory reaction. In other patients with MCA, MCs appear to be clonal cells, but criteria for diagnosing mastocytosis are not met. A working conference was organized in 2010 with the aim to define criteria for diagnosing MCA and related disorders, and to propose a global unifying classification of all MC disorders and pathologic MC reactions. This classification includes three types of 'MCA syndromes' (MCASs), namely primary MCAS, secondary MCAS and idiopathic MCAS. MCA is now defined by robust and generally applicable criteria, including (1) typical clinical symptoms, (2) a substantial transient increase in serum total tryptase level or an increase in other MC-derived mediators, such as histamine or prostaglandin D(2), or their urinary metabolites, and (3) a response of clinical symptoms to agents that attenuate the production or activities of MC mediators. These criteria should assist in the identification and diagnosis of patients with MCAS, and in avoiding misdiagnoses or overinterpretation of clinical symptoms in daily practice. Moreover, the MCAS concept should stimulate research in order to identify and exploit new molecular mechanisms and therapeutic targets.
组织肥大细胞 (MCs) 的激活及其在各种器官中的异常生长和积累通常在原发性 MC 疾病中发现,也称为肥大细胞增多症。然而,越来越多的患者被告知,他们的临床发现是由于 MC 激活 (MCA) 引起的,这种 MCA 既与肥大细胞增多症无关,也与明确的过敏或炎症反应无关。在其他 MCA 患者中,MC 似乎是克隆细胞,但不符合肥大细胞增多症的诊断标准。2010 年组织了一次专题会议,旨在定义诊断 MCA 和相关疾病的标准,并提出所有 MC 疾病和病理性 MC 反应的全球统一分类。该分类包括三种类型的“MCA 综合征”(MCASs),即原发性 MCAS、继发性 MCAS 和特发性 MCAS。MCA 现在通过可靠且普遍适用的标准来定义,包括 (1) 典型的临床症状,(2) 血清总类胰蛋白酶水平显著升高或其他 MC 衍生介质(如组胺或前列腺素 D2)或其尿代谢物增加,以及 (3) 临床症状对减轻 MC 介质产生或活性的药物的反应。这些标准应有助于识别和诊断 MCAS 患者,并避免在日常实践中误诊或过度解释临床症状。此外,MCAS 概念应刺激研究,以识别和利用新的分子机制和治疗靶点。